Term ends Apr 16, 2038 · High confidence
20-year base term ends Nov 9, 2037
Held by Keros Therapeutics, Inc.
Filed May 24, 2021 as application 17/327,914 · Granted Aug 8, 2023
Base term plus 158 days of patent term adjustment (USPTO delay)
Today
2017
2038
Clock starts
Nov 9, 2017
Nov 9, 2017
Term ends
Apr 16, 2038
Apr 16, 2038
Granted
Aug 8, 2023
Aug 8, 2023
base term
patent term adjustment
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
158
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 158 days past its 20-year base term on prosecution delay. 0 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 9, 2017, when application PCT/US2017/060960, the earliest non-provisional in its chain, was filed (this one was filed May 24, 2021) | Nov 9, 2037 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +158 days, USPTO patent term adjustment record | Apr 16, 2038 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Apr 16, 2038 | High confidence |
This family
| Application PCT/US2017/060960 | PCT application no patent term | no patent term |
| US 11,013,785 | In force Nov 2037 | Nov 2037 |
| US 11,717,558 | this patent Apr 2038 | Apr 2038 |
| US 12,350,313 | In force Nov 2037 | Nov 2037 |
| US 12,582,700 | In force no later than Nov 2037 | no later than Nov 2037 |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 25, 2021 Reel 57893, frame 306 | Seehra, Jasbir S.; Lachey, Jennifer | Keros Therapeutics, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Apr 2038
Term ends Apr 16, 2038. Maintenance fees still fall due before then
Note
The 158 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
10
later US patents cite this one
That is top 10% of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.